Gland Pharma Announces 48th AGM on Aug 25, 2026, and FY26 Dividend of ₹20/share
Gland Pharma will hold its 48th AGM on August 25, 2026. A final dividend of ₹20 per share for FY2025-26 will be paid, with a record date of August 11, 2026. Shareholders are reminded to update KYC details.
The announcement pertains to standard corporate governance procedures like AGM scheduling and dividend payout, which are expected events and do not represent a significant change in the company's business or financial outlook.
The announcement is routine in nature, providing details about the AGM and dividend, with no significant positive or negative financial impact indicated.
Gland Pharma Limited has announced the schedule for its 48th Annual General Meeting (AGM) to be held on Tuesday, August 25, 2026, at 11:00 AM IST via Video Conferencing (VC) or Other Audio Visual Means (OAVM).
The company is also issuing a final dividend of ₹20 per share for the financial year 2025-26. The record date for this dividend is Tuesday, August 11, 2026, with the payment scheduled on or before September 24, 2026.
Letters are being sent to shareholders who have not registered their email addresses, providing a weblink to access the Annual Report for FY 2025-26. The Annual Report can be accessed on the company's website: www.glandpharma.com. The direct path to the report is https://glandpharma.com/images/Gland_Pharma_AR_25-26_0726.pdf.
Details regarding e-voting are also provided. The cut-off date for e-voting is Tuesday, August 18, 2026. E-voting will commence on Saturday, August 22, 2026, at 9:00 AM IST and conclude on Monday, August 24, 2026, at 5:00 PM IST. The e-voting website is www.evoting.nsdl.com.
The announcement also serves as a reminder for shareholders holding physical securities to update their KYC details, including PAN, address, mobile number, and bank account information, as mandated by SEBI. Failure to update these details may affect payments like dividends.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.